Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | DRD4 | P21917 | 2/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 5/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.44 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.44 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | HTR3A | P46098 | 3/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6220144 | 0.98 | MAPT (0.47) | MAPTKDRTP53LMNADRD4 | |
| SCHEMBL2968890 | 0.94 | MAPT (0.50) | MAPTKDRTP53LMNADRD4 | |
| Fumaric Acid SCHEMBL3901905 | 0.89 | TP53 (0.43) | MAPTKDRTP53LMNADRD4 | |
| Maleic Acid SCHEMBL3901903 | 0.89 | TP53 (0.43) | MAPTKDRTP53LMNADRD4 | |
| SCHEMBL4729065 | 0.88 | MAPT (0.58) | MAPTKDRTP53LMNATHRB | |
| Hydrochloric Acid SCHEMBL4727330 | 0.87 | MAPT (0.57) | MAPTKDRTP53LMNATHRB | |
| SCHEMBL8653538 | 0.82 | MAPT (0.48) | MAPTTP53LMNADRD4HTR2A | |
| SCHEMBL7828988 | 0.82 | ADRB2 (0.52) | MAPTTP53LMNAHTR2ATHRB | |
| SCHEMBL2966925 | 0.81 | ADRB2 (0.55) | MAPTTP53LMNATHRBHTR1A | |
| SCHEMBL6811078 | 0.81 | MAPT (0.46) | MAPTTP53LMNADRD4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772252-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1935887-B1 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMA INC (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20090247509-A1 | Novel Heterocyclic Substituted Carbonyl Derivatives and Their Use as Dopamine D3 Receptor Ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-7550469-B2 | Heterocyclic amide derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-06-23 | — | — | US | disclosed |
| US-7521445-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-7511046-B2 | Thienoisoxazolyl- and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as D4 antagonists | AVENTIS HOKLINGS INC. (US) | 2009-03-31 | — | — | US | disclosed |
| US-7511046-B2 | Thienoisoxazolyl- and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as D4 antagonists | AVENTIS HOKLINGS INC. (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1632483-B1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMA INC (US) | 2008-10-29 | — | — | EP | disclosed |
| EP-1935887-A1 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | Aventis Pharmaceuticals, Inc. (US) | 2008-06-25 | — | — | EP | disclosed |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-5371087-A | Antipsychotic, analgesics, anticonvulsant and anxiolytic agent | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1994-12-06 | — | — | US | disclosed |
| EP-0570850-A1 | Benzo(b)thiophen-3-yl-piperazines, a process for their preparation and their use as medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-11-24 | — | — | EP | disclosed |
| US-5240927-A | Benzo[β]thiophen-3-yl piperazines as antipsychotic agents | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-08-31 | — | — | US | disclosed |
| US-5229388-A | 3-[4-(1-substituted-4-piperazinyl)butyl]-4-thiazolidinone and related compounds | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-07-20 | — | — | US | disclosed |
| US-5225412-A | Antipsychotic | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-07-06 | — | — | US | disclosed |
| EP-0511610-A1 | Benzisothiazole- and benzisoxazole-3-carboxamides, a process for their preparation and their use as antipsychotic medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-11-04 | — | — | EP | disclosed |
| US-5143923-A | Psychological disorders | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1992-09-01 | — | — | US | disclosed |
| US-5136037-A | 3-(4-substituted-4-piperazinyl)butyl-4-thiazolidinone and related compounds | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1992-08-04 | — | — | US | disclosed |
| US-5037984-A | Anticonvulsants; anxiolytic agents | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1991-08-06 | — | — | US | disclosed |
| US-4933453-A | ANTIPSYCHOTIC, ANALGESIC, ANTICONVULSANT, AND ANXIOLYTIC AGENTS | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1990-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247509-A1 | Novel Heterocyclic Substituted Carbonyl Derivatives and Their Use as Dopamine D3 Receptor Ligands | DRD3, DRD2, HTR3C | MAPT 286/4885KDR 3829/4885TP53 4562/4885 |
| US-20070161641-A1 | Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, HTR3C | MAPT 331/4885KDR 3853/4885TP53 4613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.